Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of HRS-5965 versus eculizumab in paroxysmal nocturnal hemoglobinuria
CTR20243439Phase 3Completed
- Sponsor
- Chengdu Shengdi
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-5965 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Chengdu Shengdi. Started Oct 2024; status: completed.
02
Drugs
HRS-5965
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20243439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243439.